Literature DB >> 14583497

Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen.

Arvin S Yang1, Claude E Monken, Edmund C Lattime.   

Abstract

Using a murine transitional cell carcinoma tumor model, MB49, which naturally expresses the male antigen HY, we evaluated whether tumor ignorance as determined by lack of a systemic immune response could be overcome by immunization with vaccinia expressed tumor antigen and granulocyte macrophage colony-stimulating factor. Systemic tumor ignorance of MB49 was demonstrated by the lack of a splenic HY-specific CTL response in MB49-bearing female mice. In contrast, we demonstrated HY-specific CTL priming in the draining lymph nodes. MB49-bearing female B6 mice were immunized with VVHY+VVGMCSF intratumorally or in the contralateral flank. Intratumoral VVHY, VVGMCSF, and keyhole limpet hemocyanin (to produce CD4 help) generated splenic HY-specific CD8 CTLs, whereas immunization with the combination in the contralateral flank or single agents given intratumorally failed to yield a splenic response. Purified male T cells injected intratumorally, as a source of HY antigen, also generated a HY-specific response, whereas contralateral immunizations did not. These finding expand the understanding of tumor immunological ignorance and support intratumoral vaccination as a strategy for immunotherapy of established tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583497

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Oncolytic viruses: focusing on the tumor microenvironment.

Authors:  C R de Vries; H L Kaufman; E C Lattime
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

2.  Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3.

Authors:  J Musil; L Kutinova; K Zurkova; P Hainz; K Babiarova; J Krystofova; S Nemeckova
Journal:  Cancer Gene Ther       Date:  2014-02-21       Impact factor: 5.987

3.  Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.

Authors:  Laura Masuelli; Laura Marzocchella; Chiara Focaccetti; Florigio Lista; Alessandra Nardi; Antonio Scardino; Maurizio Mattei; Mario Turriziani; Mauro Modesti; Guido Forni; Jeffrey Schlom; Andrea Modesti; Roberto Bei
Journal:  Cancer Immunol Immunother       Date:  2010-04-04       Impact factor: 6.968

4.  Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Authors:  Howard L Kaufman; Gail Deraffele; Josephine Mitcham; Dorota Moroziewicz; Seth M Cohen; Karl S Hurst-Wicker; Ken Cheung; David S Lee; Joseph Divito; Magalese Voulo; Julie Donovan; Kate Dolan; Kelledy Manson; Dennis Panicali; Ena Wang; Heidi Hörig; Francesco M Marincola
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

5.  PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival.

Authors:  Kevin P Nikitczuk; Rene S Schloss; Martin L Yarmush; Edmund C Lattime
Journal:  J Cancer Ther       Date:  2013-01-01

6.  Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.

Authors:  M R Newton; E J Askeland; E D Andresen; V A Chehval; X Wang; R W Askeland; M A O'Donnell; Y Luo
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response.

Authors:  Laura Poillet-Perez; Daniel W Sharp; Yang Yang; Saurabh V Laddha; Maria Ibrahim; Praveen K Bommareddy; Zhixian Sherrie Hu; Joshua Vieth; Michael Haas; Marcus W Bosenberg; Joshua D Rabinowitz; Jian Cao; Jun-Lin Guan; Shridar Ganesan; Chang S Chan; Janice M Mehnert; Edmund C Lattime; Eileen White
Journal:  Nat Cancer       Date:  2020-09-18

8.  Current and emerging therapies for the treatment of pancreatic cancer.

Authors:  Rebecca A Moss; Clifton Lee
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

9.  Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine.

Authors:  Eduardo Lasalvia-Prisco; Emilio Garcia-Giralt; Silvia Cucchi; Jesús Vázquez; Leonard Robinson; John Dalton
Journal:  Biologics       Date:  2007-06

10.  Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells.

Authors:  Laura Masuelli; Massimo Fantini; Monica Benvenuto; Pamela Sacchetti; Maria Gabriella Giganti; Ilaria Tresoldi; Paolo Lido; Florigio Lista; Federica Cavallo; Patrizia Nanni; Jeffrey Schlom; Andrea Modesti; Roberto Bei
Journal:  J Transl Med       Date:  2014-05-10       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.